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ABSTRACT 
 
Rationale: Deficiency of secreted IgM (sIgM-/-) accelerates atherosclerosis in Ldlr-/-mice. 
Several atheroprotective effects of increased levels of IgM antibodies have been suggested, 
including preventing inflammation induced by oxidized LDL and promoting apoptotic cell 
clearance. However, the mechanisms by which the lack of sIgM promotes lesion formation 
remain unknown.  
Objective: To identify the mechanisms by which sIgM deficiency accelerates atherosclerosis 
in mice. 
Methods and Results: We here show that both sIgM-/- and Ldlr-/-sIgM-/- mice develop 
increased plasma IgE titers due to impaired generation of B cells expressing the low affinity 
IgE receptor CD23, which mediates the clearance of IgE antibodies. We further report that Ldlr-
/-sIgM-/- mice exhibit increased numbers of activated mast cells and neutrophils in the 
perivascular area of atherosclerotic plaques. Treatment with an anti-IgE neutralizing antibody 
fully reversed vascular inflammation and accelerated atherosclerotic lesion formation in 
cholesterol-fed Ldlr-/-sIgM-/- mice. 
Conclusions: Thus, our data identify a previously unsuspected mechanism by which sIgM 
deficiency aggravates atherosclerosis. 
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INTRODUCTION 
 
Secreted IgM (sIgM) antibodies are produced very early in life. In unchallenged 
conditions a major portion of sIgM consists of natural IgM, which are mainly derived from innate 
B-1 B cells. B-1 B cells predominately localize in the peritoneal cavity, where they are 
subdivided into B-1a and B-1b B cells, and in contrast to conventional B cells, they produce 
antibodies in the absence of cognate T cell help1, 2. 
A large part of natural IgM recognize oxidation-specific epitopes (OSE)3, which are 
present on OxLDL, dying cells and microparticles3-5. Both epidemiological and experimental 
studies have suggested a protective role for anti-OxLDL sIgM in atherosclerosis and CVD6. 
These effects are thought to be mediated by the ability of OSE-specific IgM to block and 
neutralize the proatherogenic effects of OxLDL and/or promote the clearance of dying cells 
and cellular debris6. 
However, OSE-specific IgM constitute only ~30% of total IgM3, which also possess 
important homeostatic functions such as regulation of conventional B-2 cell development7, 8. 
This is of particular interest as B-2 cells have been shown to aggravate atherosclerosis6. 
Therefore, sIgM may also have an important modulatory function in atherosclerotic plaque 
formation that is independent of directly limiting plaque inflammation. 
Notably, Ldlr-/- mice deficient in secreted IgM (sIgM-/-) exhibit accelerated lesion 
formation9, but there is no evidence that this effect is a direct result of defective apoptotic cell 
clearance in the plaque9. This indicates that sIgM harbor currently unknown atheroprotective 
properties, which are responsible for the robust proatherogenic effect of sIgM deficiency.  
 
 
MATERIALS AND METHODS 
 
Mice, treatments and diets 
Ldlr-/- mice (on C57BL/6 background), sIgM-/- (on 129 background) and Rag1-/- mice 
were originally bought from The Jackson Laboratories (USA). SIgM-/- mice were backcrossed 
onto C57BL/6 background for at least 10 generations. Ldlr-/-sIgM-/- mice were generated by 
intercrossing Ldlr-/- and sIgM-/- mice. To induce atherosclerosis mice were fed an atherogenic 
diet (0.2% cholesterol, 21% fat; E15721-347 bought from Ssniff, Germany) and treated with 
either an anti-IgE neutralizing antibody (clone R1E4), which binds free IgE only or a control 
IgG (Jackson Immunoresearch Inc.) where indicated. 
Plasma or serum cholesterol and triglyceride quantification 
Total cholesterol and triglycerides in plasma or serum were measured under 
standardized conditions in an ISO 15189 accredited medical laboratory on Beckman Coulter 
AU5400 (Beckman Coulter) or Roche Cobas 8000 (Roche) instruments.  
 
Quantification of size and macrophage content of atherosclerotic lesions 
Size and macrophage content of atherosclerotic lesions were evaluated by computer 
assisted image analysis using Adobe Photoshop Elements 6.0 and ImageJ software as 
described previously10, 11. 
 
Mast cell and neutrophil staining 
Mast cells and neutrophils were visualized in the perivascular area of cross sections as 
described previously12, 13. 
 
Total and free IgE antibody quantification by ELISA 
Total and free IgE serum titers were quantified by ELISA with the Mouse IgE ELISA 
MAX kit (Biolegend). To determine free IgE serum levels, plates were coated with the anti-IgE 
antibody R1E4 antibody at 5 µg/mL. 
 
 
 
	 CIRCRES/2016/ 309606/R2	
4		
Bone marrow derived mast cell stimulation 
Bone marrow derived mast cells (BMMCs) were grown by culturing bone marrow cells 
at a density of 0.25x106 cells in RPMI containing 10% fetal bovine serum (FBS), 2 mmol/L l-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin (all from PAA) and 10% murine 
Interleukin-3 containing supernatant (supernatant from WEHI cells overexpressing murine 
Interleukin-3) for 4 weeks. BMMCs (5x105) were incubated with sterile plasma (1:12 dilution in 
medium) from Ldlr-/-sIgM-/- mice of study 3 (Online Table I) for 2 hours at 37°C, after which 
supernatant was collected. IL-6 was determined by ELISA according to the manufacturer’s 
protocol (BD Biosciences). 
 
Peritoneal macrophage stimulation 
Macrophages were isolated from the peritoneal cavity of Rag1-/- mice by peritoneal 
lavage with RPMI (Gibco) containing 1% FBS (Gibco) and 1% penicillin and streptomycin. 
Cells were plated in a 96-well (flat bottom) for at least 2 hours prior to stimulation to allow 
adherence. Then, cells were stimulated with 10% sterile plasma from Ldlr-/-sIgM-/- mice of study 
3 (Online Table I) for either 4 or 48 hours at 37°C, after which il-6 mRNA (4 hours) or cell 
viability (48 hours) were determined by Real-time PCR and CellTiter glo luminescent ell 
viability assay (Promega), respectively. 
 
Soluble CD23 quantification by ELISA 
Serum soluble CD23 was determined by ELISA using a rabbit anti-CD23 antibody and 
anti-rabbit IgG conjugated to alkaline phosphatase (Sigma; A3687) on a Synergy 2 
luminometer (BIO-TEK). 
 
Flow cytometry 
Flow cytometry analysis in splenic, bone marrow and peritoneal cells was performed as 
described previously10. 
 
Total RNA extraction, cDNA synthesis and Real-time PCR analysis 
Total RNA was extracted with the peqGold total RNA kit (Peqlab) and cDNA was 
synthesized using the High capacity cDNA reverse transcription kit (Applied Biosystems). 
Quantitative Real-time PCR analysis was performed with the KAPA SYBR green FAST BioRad 
icycler kit (Peqlab). For il-6 and germline IgE mRNA quantification, 36B4 or CD19 were used 
as reference genes respectively and the data are expressed as fold change over sIgM+/+ or 
Ldlr-/-sIgM+/+ mice.  
 
Statistical analyses 
Statistical analyses were performed using Graph Pad Prism 5 for Windows (Graph Pad 
Software). Experimental groups were compared using two tailed Student’s unpaired or Mann-
Whitney test as appropriate. To analyze multiple group data, either One-Way ANOVA test 
followed by Newman-Keuls or Dunn’s or unpaired t test were performed as indicated. Data are 
presented as mean ± SEM or as mean ± SD where indicated. A P value of <0.05 was 
considered significant. 
 
 
RESULTS 
 
Secreted IgM deficiency results in strongly increased plasma IgE  
 
Patients with selective IgM deficiency exhibit increased levels of plasma IgE14. Although 
sIgM-/- mice have been reported to display disturbed basal humoral immunity15	IgE responses 
in these mice have not been investigated. We discovered that plasma IgE levels were >8 fold 
higher in both young and old sIgM-/- mice compared to sIgM+/+ controls (Figure 1A, B). Similar 
to sIgM-/- mice, Ldlr-/-sIgM-/- mice fed a regular chow also display robustly increased plasma 
IgE (>9 fold) (Figure 1C). Although atherogenic diet feeding itself has been shown to increase 
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plasma IgE levels16, Ldlr-/-sIgM-/- mice that were fed an atherogenic diet for 16 weeks display 
much higher levels of IgE in their plasma (>5-fold) compared to the moderately increased 
levels in control Ldlr-/- mice (Figure 1D). Ldlr-/-sIgM-/- mice that were fed an atherogenic diet for 
16 weeks developed increased atherosclerosis in the aortic arch, thoracic and abdominal aorta 
compared to control Ldlr-/- mice (Figure 1E) despite similar serum cholesterol and triglyceride 
levels (Online Table I; study 1), which is consistent with Lewis et al9. Because a proatherogenic 
role for IgE is supported by both experimental16 and epidemiological studies17, we 
hypothesized that increased IgE may mediate the aggravated atherosclerosis in sIgM-/- mice. 
 
IgE neutralization reverses the accelerated atherosclerosis in Ldlr-/-sIgM-/- mice 
 
To investigate whether increased IgE titers contribute to accelerated atherosclerosis in 
these mice, Ldlr-/-sIgM-/- or Ldlr-/- mice were fed an atherogenic diet for 6 weeks and at the same 
time were treated with either a neutralizing anti-IgE antibody (R1E4) or a control antibody (Ctrl), 
respectively. Anti-IgE treatment resulted in complete neutralization of free IgE antibodies 
(Figure 2A). Consistent with Lewis et al9, Ldlr-/-sIgM-/- mice treated with the control antibody 
developed 30% increased atherosclerosis in the aortic root compared to Ldlr-/- mice. 
Importantly, enhanced lesion formation in Ldlr-/-sIgM-/- mice was fully reversed by anti-IgE 
treatment (Figure 2B). Moreover, anti-IgE treatment did not change plasma cholesterol and 
triglyceride levels (Online Table I). Furthermore, similar data were obtained when Ldlr-/-sIgM-/- 
mice were fed an atherogenic diet for 8 weeks (Online Table I, study 3; and Figures 2C,D) and 
treated with a control antibody or a neutralizing anti-IgE as described above. Anti-IgE treatment 
resulted in complete neutralization of free IgE antibodies and a 40% decrease of lesion size in 
the aortic origin (Figure 2C, D). A similar trend was found in the entire aorta by en face lesion 
size for both studies mentioned above (Online Figure IA,B). These data indicate that the 
pathogenesis of atherosclerotic lesion formation in mice lacking sIgM is prominently driven by 
IgE antibodies. Interestingly, anti-IgE treatment in Ldlr-/- mice fed an atherogenic diet for 8 
weeks had no effect on the extent of lesion formation compared to Ctrl Ab treated mice (Online 
Figure IB) despite an efficient neutralization of plasma IgE (Online Figure IC) and similar body 
weights (anti-IgE; 25.2 ±1.6g; Ctrl: 24.4 ±1.3g) and total cholesterol levels (anti-IgE; 1506 
±194mg/dL; Ctrl: 1403 ±75mg/dL). Notably, plasma IgE levels in these mice were equivalent 
to wild-type mice, which suggests that the proatherogenic effect of IgE requires higher levels 
such as found in Ldlr-/-sIgM-/- mice. 
Because IgE antibodies robustly activate mast cells via the FcεRI and mast cells have 
been shown to promote atherosclerotic plaque formation12, 18, we examined the activation 
status of mast cells in the perivascular area of aortic root lesions. We found that Ldlr-/-sIgM-/- 
mice displayed a significantly increased frequency of activated mast cells compared to Ldlr-/- 
mice, while this effect was reversed by anti-IgE treatment (Figure 3A and Online Figure IIA,B). 
Moreover, we have recently shown that neutrophils, which promote atherosclerosis19 are 
recruited in the vessel wall upon mast cell activation13. In line with this, we found that the 
perivascular area of atherosclerotic lesions of Ldlr-/-sIgM-/- mice had significantly higher 
numbers of neutrophils compared to Ldlr-/- mice, which was fully reversed by anti-IgE treatment 
(Figure 3B and Online Figure IIA,B). To assess the proatherogenic properties of pooled plasma 
IgE from Ldlr-/-sIgM-/- mice in vitro, we performed cell-based stimulation assays using plasma 
from Ctrl and anti-IgE treated Ldlr-/-sIgM-/- mice (study 3) that was collected in a sterile manner. 
Stimulation of bone marrow derived mast cells with plasma collected from control antibody-
treated Ldlr-/-sIgM-/- mice (study 3) at the end of the experiment resulted in robust IL-6 secretion 
(which was >9 fold higher compared to stimulation with Ldlr-/- plasma; data not shown), 
whereas stimulation with plasma from anti-IgE treated Ldlr-/-sIgM-/- mice failed to do so (Figure 
3C). Moreover, stimulation of peritoneal macrophages with plasma from control antibody-
treated Ldlr-/-sIgM-/- mice (study 3) resulted in higher IL-6 mRNA and decreased cell survival, 
compared to stimulation with plasma from anti-IgE treated Ldlr-/-sIgM-/- mice (Figure 3D,E). 
Interestingly, we found no difference in lesional macrophage content between Ldlr-/-sIgM-/- and 
Ldlr-/- mice (Online Figure III). These data indicate that sIgM deficiency increases the levels of 
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proinflammatory IgE, which in turn promote vascular inflammation and accelerate the 
development of atherosclerosis. 
 
B cells expressing the low affinity IgE receptor CD23 are reduced in sIgM-/- mice  
 
In order to investigate whether the increased IgE levels were due to increased IgE 
production, we quantified IgE producing B cells as defined in Online Figure IVA. We found that 
sIgM-/- and sIgM+/+ mice had equivalent numbers of class switched B cells expressing IgE in 
the spleen (Online Figure VA). In addition, we found no differences in IgE secreting plasma 
cells (CD138+ B220-) and plasmablasts (CD138+ B220+) in the bone marrow (Online Figure 
VB) and the spleen (Online Figure VC) between sIgM-/- and sIgM+/+ mice. Similar data were 
obtained for naïve B cells (Online Figure VB, C). In line with these data, germline IgE mRNA 
in the spleen was not different between sIgM-/- and sIgM+/+, or between Ldlr-/-sIgM-/- and Ldlr-/-
sIgM+/+ mice (Online Figure IVD, E). 
B cells that express CD23, which is the low affinity receptor for IgE, have previously 
been shown to mediate clearance of IgE antibodies20-22. Interestingly, we found that Ldlr-/-sIgM-
/- mice had reduced CD23-expressing B cells in the spleen (Figure 4A) and the peritoneal cavity 
(Figure 4B) compared to Ldlr-/-sIgM+/+ controls. Similar data were obtained in the spleen and 
the peritoneal cavity of sIgM-/- and sIgM+/+ mice (data not shown). In addition, we show that the 
reduction in splenic CD23-expressing B cells (consisting of follicular and CD23+ transitional 
stage 2 B cells; FO/T2) in Ldlr-/-sIgM-/- mice is due to altered splenic B cell maturation, which 
results in increased MZ and CD21+ CD23- B cells and concomitantly reduced FO B cells 
(Figure 4C). Interestingly, immature B cells that have newly escaped from the bone marrow 
(newly formed (NF) and transitional stage 1 (T1) B cells) are not altered in Ldlr-/-sIgM-/- mice 
(Figure 4C), which suggests that secreted IgM regulate MZ and FO B cell differentiation by 
directly modulating the splenic microenvironment. Moreover, we found decreased levels of 
soluble CD23 in the plasma of Ldlr-/-sIgM-/- mice (Figure 4D), which further supports an 
impaired generation of CD23 expressing B cells. Taken together, the strongly reduced 
numbers of CD23 expressing B cells in the spleen and peritoneal cavity of Ldlr-/-sIgM-/- mice 
offer a mechanistic explanation for the accumulation of IgE in these mice. 
 
 
DISCUSSION 
 
IgM Abs that display reactivity towards OxLDL and apoptotic cells3 have been 
suggested to confer an atheroprotective effect by blocking OxLDL-induced foam cell formation 
and promoting apoptotic cell clearance6. Lewis et al, reported that mice lacking sIgM developed 
enhanced atherosclerosis. However, Ldlr-/-sIgM-/- mice did not show increased accumulation of 
apoptotic cells within the lesions, compared to their controls9. 
Kyaw et al demonstrated that splenectomy of atherosclerotic Apolipoprotein E deficient 
(Apoe-/-) mice reduced plasma IgM levels by approximately 50% and resulted in increased 
atherosclerosis, which was reversed following administration of B-1a cells that are able to 
secrete IgM23. However, despite the fact that transfer of B-1a cells from IgM competent mice 
reversed the proatherogenic effect of splenectomy compared to transfer of B-1a cells from 
sIgM ko mice, the deposition of MDA-LDL and apoptotic cells was not different between the 
two groups. Thus, reduction of total IgM in the context of splenectomy may activate unknown 
proatherogenic mechanisms that are controlled by the pool of total IgM. 
In fact, the studies described above do not support the notion that the protective effect 
of the entire pool of sIgM antibodies is mediated via reduced foam cell formation or improved 
apoptotic cell clearance. Of note, the difference in plaque size between atherosclerosis-prone 
sIgM-/- and control mice is larger when fed a low fat semi-synthetic diet compared to 
atherogenic diet9. These data suggest that the accelerated atherosclerosis in Ldlr-/-sIgM-/- mice 
is predominately mediated via mechanisms that are already present in unchallenged sIgM-/- 
mice and do not depend excessive hypercholesterolemia. Here, we report that sIgM-/- mice 
display strongly elevated IgE levels, which are responsible for accelerated atherosclerosis in 
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these mice. Notably, splenectomy in humans, which also causes a strong reduction in IgM 
levels24 and associates with increased risk for myocardial infarction6, has been reported to 
result in elevated plasma IgE titers25. Thus, even though splenectomy affects multiple immune 
cell types, it is tempting to hypothesize that IgE may also in part be responsible for accelerated 
atherosclerosis upon splenectomy in humans. 
Our data argue against elevated plasma IgE as a consequence of increased IgE 
production. We propose that impaired generation of B cells expressing the low affinity receptor 
CD23, which mediates the clearance of circulating IgE, results in plasma IgE accumulation in 
sIgM-/- mice. Considering that plasma IgE are increased upon hypercholesterolemia in mice 
and correlate with CVD risk in humans6, 16, 17, it is tempting to hypothesize that CD23+ B cells 
may be critically involved in preventing atherosclerosis progression by promoting the removal 
of IgE from the circulation.  
Moreover, we demonstrate an increased portion of activated mast cells and neutrophils 
in the perivascular area of atherosclerotic lesions of Ldlr-/-sIgM-/- mice, which was driven by the 
increased IgE levels in these mice. Although the numbers of mast cells and neutrophils are 
relatively low compared to macrophages in plaques, we and others have previously 
established that both mast cells12 and neutrophils19 exhibit strong proatherogenic properties. 
Notably, we found even higher numbers of mast cells in Ldlr-/-sIgM-/- mice compared to our 
previous studies12. Moreover and in line with a previous study16, we demonstrate that IgE have 
the capacity to promote IL-6 production by macrophages while prolonged stimulation with IgE-
containing plasma induces increased cell death in macrophages. This may provide an 
explanation why despite increased IgE-mediated vascular inflammation the number of lesional 
macrophage is not different.  
Besides the proatherogenic role of absent or reduced IgM, previous studies reported 
atheroprotective effects in association with increased levels of OxLDL-specific IgM. For 
example, immunization of Ldlr-/- mice with heat inactivated pneumococcal extracts resulted in 
increased levels of the prototypic PC-specific natural IgM T15/E06 that binds OxLDL and 
apoptotic cells, and decreased atherosclerotic lesion formation11. Similarly, vein graft 
atherosclerosis was reduced when T15/E06 was passively infused into Apoe-/- mice26. 
Furthermore, we recently showed that mice lacking the sialic acid binding immunoglobulin-like 
lectin G, which display increased numbers of B-1 cells and elevated levels OxLDL-specific 
IgM, were less susceptible to atherosclerosis10. In addition, Rosenfeld et al, demonstrated that 
Apoe-/-Rag-/- mice that were adoptively transferred with B-1b cells that produced IgM antibodies 
with specificity for OSE in vivo, showed reduced development of atherosclerosis compared to 
PBS injected controls27. Together these studies suggest a protective role of high levels of B-1 
cell derived OSE-specific IgM antibodies that recognize OxLDL and apoptotic debris. However, 
we believe that the effects seen in mice lacking all sIgM address a more fundamental role of 
sIgM in immune regulation, which goes beyond the potential mechanisms by which high levels 
of natural IgM protect against atherosclerosis. Along this line, it is important to note that sIgM-
/- mice lack the entire repertoire of soluble IgM antibodies, which includes natural IgM and IgM 
derived from conventional B-2 cells. In contrast to B-1 cells B-2 cells exhibit a more diverse 
repertoire of antibody specificities, which thereby contributes largely to the diversity of the total 
IgM pool that mediates recognition of various types of self-antigens. The latter is particularly 
important as self-antigen mediated B cell receptor signaling dictates proper mature B-2 cell 
(follicular and marginal zone B cells) development in the spleen28. Consistent with this, we 
show that splenic B-2 cell development is disturbed in both sIgM-/- and Ldlr-/-sIgM-/- mice and 
results in strongly impaired CD23-expressing B cell generation, which as mentioned above are 
responsible for the clearance of IgE antibodies. Thus, sIgM antibodies influence 
atherosclerosis in multiple ways. Indeed, both total IgM and MDA-LDL specific IgM are 
inversely associated with CVD complications in individuals of the Anglo-Scandinavian Cardiac 
Outcomes Trial29. 
Interestingly, recent work indicates that IgE promote lupus like autoimmunity in mice30 
and that the presence of autoreactive IgE positively associates with disease activity in SLE 
patients31. Notably, lupus-prone mice lacking sIgM develop enhanced autoimmune pathology 
compared to their controls32. Our findings provide an alternative explanation in which increased 
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IgE in mice lacking sIgM may contribute to the aggravated autoimmunity. This is particularly 
interesting considering that SLE patients display premature atherosclerosis and are at high 
risk for CVD complications, which cannot be explained by the traditional risk factors33. Thus, 
our data suggest that anti-IgE treatment could be considered as a therapeutic option for 
accelerated atherosclerosis in autoimmune diseases. 
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NOVELTY AND SIGNIFICANCE 
What is known? 
• Deficiency of secreted IgM (sIgM) Abs results in accelerated atherosclerosis 
• sIgM Abs regulate B cell development 
• B cells are important players in the pathogenesis of atherosclerosis 
 
What new information dies this article contribute? 
• Deficiency of sIgM Abs leads to robustly increased IgE Abs in plasma 
• Increased plasma IgE Abs drive accelerated atherosclerosis in mice lacking sIgM Abs 
• sIgM Abs aggravate atherosclerosis by regulating splenic B cell development 
 
Total and OxLDL-specific IgM Abs have been shown to inversely associate with CVD risk. In 
line with this, mice lacking sIgM Abs develop accelerated atherosclerosis. However, the 
underlying mechanism has been unknown. We show here that sIgM deficient mice display 
strongly increased IgE levels in plasma that are responsible for the increased atherosclerosis 
in these mice. These data suggest that sIgM impact atherosclerosis via regulation of B cell 
functions and humoral immunity.  
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FIGURE LEGENDS 
 
Figure 1. Increased plasma IgE titers in sIgM-/- mice. Total plasma IgE antibody levels in 
(A) 12-14 week old (n=9-11 mice per group) and (B) 28 week old (n=10 mice per group) sIgM+/+ 
(light blue bars) and sIgM-/- (dark blue bars) mice measured by ELISA. (C) Total plasma IgE of 
Ldlr-/-sIgM-/- (light blue bar) or Ldlr-/-sIgM-/- mice (dark blue bar) fed a regular chow diet (n=6 
mice per group). (D) Total plasma IgE and (E) representative photomicrographs (left) and dot 
plot (right) show the quantification of en face atherosclerotic lesion size expressed as 
percentage of total aortic area of Sudan VI stained aortas of female Ldlr-/-sIgM+/+ (light blue 
bar) or Ldlr-/-sIgM-/- (dark blue bar) mice that were fed an atherogenic diet for 16 weeks (Online 
Table I, study 1, n=13-15 mice per group). Results are represented as mean ± SEM. 
**P<0.01***P<0.001, ****P<0.0001 (Mann-Whitney or unpaired t test). 
 
 
Figure 2. IgE neutralization reverses accelerated atherosclerosis in Ldlr-/-sIgM-/- mice.  
(A) Levels of free plasma IgE antibodies and (B) representative photomicrographs of H&E-
stained aortic root lesions (50x) and dot plot of the average lesion size in the aortic origin 
expressed as µm2/section (400µm) of female Ldlr-/- (light blue) or Ldlr-/-sIgM-/- (dark blue) mice 
fed an atherogenic diet for 6 weeks and injected intraperitoneally once every week with an 
anti-IgE neutralizing antibody (R1E4) or a control IgG. Ldlr-/- + Ctrl IgG, n=14; Ldlr-/-sIgM-/- + 
Ctrl IgG, n=16; Ldlr-/-sIgM-/- + anti-IgE, n=15 (Online Table I, study 2). (C) Levels of free plasma 
IgE antibodies and (D) representative photomicrographs of H&E-stained aortic root lesions 
(50x) and dot plot of the average lesion size in the aortic origin expressed as µm2/section 
(400µm) of female Ldlr-/-sIgM-/- mice fed an atherogenic diet for 8 weeks and injected 
intraperitoneally once every week with an anti-IgE neutralizing antibody (R1E4) or a control 
IgG. Ldlr-/-sIgM-/- + Ctrl IgG, n=10; Ldlr-/-sIgM-/- + anti-IgE, n=8 (Online Table I, study 3). Data 
are represented as mean ± SEM, *P<0.05, ****P<0.0001 (One-Way ANOVA followed by (A) 
Dunn’s (B) Newman-Keuls test, and (C,D) unpaired t test), scale bar: 200µm. 
 
 
Figure 3. Elevated plasma IgE promote mast cell activation, neutrophil recruitment and 
macrophage cell death in Ldlr-/-sIgM-/- mice. 
(A) Representative photomicrographs of chloroacetate esterase stained mast cells (MC) 
(upper left; 10x, bottom left; 40x) and dot plot of the average percentages of perivascular 
activated MC, and (B) dot plot of average numbers of neutrophils in the perivascular area of 
atherosclerotic lesions of female Ldlr-/- (light blue) or Ldlr-/-sIgM-/- (dark blue) mice fed an 
atherogenic diet for 6 weeks and injected intraperitoneally once every week with an anti-IgE 
neutralizing antibody (R1E4) or a control IgG. Ldlr-/- + Ctrl IgG, n=13; Ldlr-/-sIgM-/- + Ctrl IgG, 
n=15; Ldlr-/-sIgM-/- + anti-IgE, n=14 (Online Table I, study 2). (C) IL-6 secretion by bone marrow 
derived mast cells, (D) il-6 mRNA production and (E) cell survival of peritoneal resident 
macrophages stimulated with pooled plasma of Ldlr-/-sIgM-/- mice (Online Table I, study 3), 
which were fed an atherogenic diet for 8 weeks and treated with a control antibody or a 
neutralizing anti-IgE measured by (C) ELISA, (D) RT-PCR, or (E) a luminescent cell viability 
assay. Data represent measurements of triplicate or quadruplicate stimulations and are 
represented as mean ± SEM, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 (One-Way 
ANOVA followed by (A) Newman-Keuls, or (B) unpaired t test, and (C,D,E) unpaired t test). 
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Figure 4. Reduced CD23+ B cells in Ldlr-/-sIgM-/- mice. (A) Flow cytometry plots (left) and 
bars (right) show the absolute numbers splenic CD23+ B cells (defined as B220+IgM+CD43-
CD23+) in Ldlr-/-sIgM+/+ (light blue bar) and Ldlr-/-sIgM-/- (dark blue bar) mice. (B) Flow cytometry 
plots (left) and bars (right) represent the frequency of peritoneal CD23+ B cells within B-2 cells 
(as defined in Online Figure IIIB) in Ldlr-/-sIgM+/+ (light blue bar) and Ldlr-/-sIgM-/- (dark blue bar) 
mice. (C) Flow cytometry plots (left) and bars (right) represent absolute numbers of FO/T2 
(blue), MZ (purple), CD21+CD23- B cells (red), T1 (green) and NF (grey) cells (as defined in 
Online Figure IIIC) in Ldlr-/-sIgM+/+ (light blue bar) and Ldlr-/-sIgM-/- (dark blue bar) mice. (D) 
Bars show plasma soluble CD23 in Ldlr-/-sIgM+/+ (light blue bar) and Ldlr-/-sIgM-/- (dark blue bar) 
mice. All results are represented as mean ± SEM, n= 6 mice per group, *P<0.05, **P<0.01, 
***P<0.001 (Mann-Whitney or unpaired t test).  
 
 
